Advances in Vaccine Delivery Systems: Approaches, Obstacles, and Opportunities

Prasit Roy*[1#], Sourav Mondal[2#], Prasanna Roy[3], Suvojit Mondal[4], Souvik Ghosal[5]

[1]Assistant Professor, Department of Pharmaceutics, Gandhari College (School of Pharmacy), Garhbari, Nazir Bazar, West Bengal -721655, India. **Email:** royprasit403@gmail.com
[2]M.Pharm (Pharmaceutics), Bengal College of Pharmaceutical Sciences and Research, Bidhannagar, Durgapur-713212, West Bengal, India. **Email:** hellosourav.in@gmail.com
[3]Assistant Professor, Department of Pharmaceutical Chemistry, Gandhari College (School of Pharmacy), Garhbari, Nazir Bazar, West Bengal -721655, India. **Email:** royprasanna09@gmail.com
[4]Assistant Professor, Department of Pharmacology, SKM Institute of Pharmaceutical Sciences and Research, Lohapur, Nalhati, Birbhum, West Bengal - 731237, India. **Email:** suvojitmondal29611@gmail.com
[5]M.Pharm (Pharmaceutics), Dr. B.C Roy College of Pharmacy and Allied Health Sciences, Durgapur- 713212, West Bengal, India. **Email:** souvikghosal887@gmail.com

[#]Contributed Equally
*Corresponding author: Prasit Roy
E-mail: royprasit403@gmail.com

Abstract

Vaccines represent cost-effective and safe interventions that give substantial health and profitable benefits to individualities and populations. The US vaccine enterprise that supports all aspects of immunization continues to encourage invention. Traditional vaccine delivery methods lack specificity in targeting a particular antigen for the development of acquired immunity through specific antibodies. Recent progress in vaccine delivery has demonstrated that incorporating adjuvants in vaccine preparations or delivering them using carriers can enhance targeting capabilities, reduce immunogenicity, and significantly boost the immune response. The use of colloidal carriers, including as liposomes, niosomes, microspheres, virosomes, contagion-like patches [VLPs], antigen cochleates, dendrimers, and carbon nanotubes, for vaccine distribution has been thoroughly studied. Moreover, the surface modification of these carriers with ligands, functional groups, and monoclonal antibodies has been explored to improve the immune appreciation potential of vaccines by promoting the isolation of antigen-specific memory T-cells. A comprehensive overview of recent developments in the various colloidal distribution systems for vaccines is presented in this review. It outlines the immune responses triggered by these systems, their underlying mechanisms, and showcases relevant case studies in a clear and concise manner.

Key words: Vaccines, immunization, targeting, colloidal, niosomes, antigen-specific.

ABBREVIATIONS

DNA- Deoxyribonucleic acid; FDA- Food and Drug Administration; ACPs- Antigen-Presenting Cells; MHC- Major Histocompatibility Complex; HIV- Human Immunodeficiency Virus; MMR vaccine- Measles, Mumps, and Rubella vaccine; HAV- Hepatitis A virus

1. Introduction

A vaccination is a chemical that, though it's not necessarily an infection, increases the immune system's ability to fight off disease. DNA encoding pathogen antigenic proteins, dead or attenuated pathogens, or parts of pathogens are present in most vaccines[1]. Sub-unit vaccines are not very immunogenic, despite being very specific and selective in their reaction with antibodies, sometimes do not show these reactions in circumstances such as modifications to the epitopic identification center of the antibody. However, by feeding the immune system in a way that elicits a specific and powerful immunological response, the pathogenic organism's subunits—such as proteins and carbohydrates—have the selectivity and specificity that can be leveraged to generate strong and long-lasting immune responses [2]. Oil-based adjuvants, such as Freund adjuvant, can be used to distribute antigens and reduce the number of vaccination doses required. However, because of safety concerns, such as the development of granulomas at the injection site, these adjuvants are not frequently used. The FDA has approved the use of aluminium hydroxide and aluminium phosphate, both available as alum, as adjuvants for use in humans [3]. Critical issues include selective targeting and distribution, as well as the presentation of antigens on the surface of professional antigen-presenting cells [APCs], in the design and development of next-generation vaccines intended to induce both humoral and cell-intermediated response. Generally speaking, humoral sensitive reactions that promote infection are the goal of preventive immunization against infectious diseases. B cells that produce antibodies act as an intermediary in this humoral susceptible response However, the activation of cytotoxic T lymphocytes [CTLs], which have the ability to precisely recognize and lyse infected cells or transformed tumor cells, is necessary for therapeutic immunization against virally infected cells and tumor cells. For example, conflation of antigens within APCs following immunization with live downgraded infection is the best way to induce Major Histocompatibility Complex [MHC] class I confined CTL exertion. Nonetheless, vaccination with live vaccines carries the risk of raising concerns. Therefore, it is necessary to find vaccine delivery mechanisms that allow nonreplicating antigen to be introduced into the MHC class I donation pathway beforehand. Similarly, MHC class II limited activation of T-coadjutor cells [Th cells] is required for the generation of efficacious humoral and cellular responses. In addition to alternative delivery methods. Among other delivery systems, as described in this theme issue of Advanced Drug Delivery Reviews, virosomes feel immaculately suited for delivery of antigens into both MHC pathways [4]. The use of virosomes as carrier vehicles for DNA and protein antigens delivered intracellularly, as well as the development of a cellular immune response against encapsulated protein antigens and

proteins generated by virosome-associated plasmids, will be the main topics of this review. In an attempt to find safer and more effective adjuvants, antigen was therefore synthesized into delivery techniques that dispense antigen in particulate form rather than solution [5]. A comparison overview of various types develop vaccine were simplified in Table 1.1.

Table: 1.1 A comparison overview of various types develop vaccine

Live attenuated vaccine	**Inactivated vaccine**	**Subunit, Polysaccharide**	**Toxoid vaccine**
MMR vaccine	Hepatitis A	Haemophilus influenzae type b [HIB] disease	Diphtheria
Rotavirus vaccine	Flu	Hepatitis B	Tetanus
Oral polio vaccine	Polio	Human papillomavirus [HPV]	
Influenza vaccine	Rabies	Whooping cough	

2. Recent trends in vaccine delivery systems

2.1 Delivery mechanism for liposomes

Liposomes are a phospholipid-based hollow spherical construct that are derived from "lipoplexes". Among the byproducts of liposomes that gather during storage are Lipoplees. A negative charge is applied to DNA by liposomes in order to neutralize the positive charge [6]. This framework uses the immunomodulatory effect of their particulate nature as an adjuvant for antibodies, and their ability to bind to cell surface lipid receptors, such as CD1a, shortly after the initiation of the supplement. Due to the PEG coating on the liposomes, the covertness liposome has a water-cherishing surface. Viral membrane protein, approved for hepatitis A and influenza in Europe, is the basis of this vaccine [7]. A Research on liposomal vaccine delivery systems is ongoing were simplified in Table 2.1 and Figure 2.1 showed Liposomal drug delivery system.

Table 2.1 Research on liposomal vaccine delivery systems is ongoing

Antigen	**Results**
BSA as an example of an antigen	More IgG and IgA in mice after liposomes are administered nasally
Influenza, hepatitis, tetanus, and HAV	Demonstrates strong human tolerance and immunity

Officially rendered inactive by formalin	Antibodies that are protective in clinical trials; presently available for purchase in Europe
GP-120's HLV-1 subunit	Causes cellular and humoral immunity following oral and intravenous injection.
P.falciparum circumsporozoite protein	In vitro, sporozoite conquest of hepatoma cells was prevented by cytotoxic T-cell lymphocytes and an antibody response.
Lysate without Vibrio cholera cells	Parenterally and orally administered liposome vaccinations proved efficacious.



Fig: 2.1 Liposomal drug delivery system

2.2 Virosomes

Given their limited radio genicity, virosomes are an essential adjuvant in the treatment of hepatitis A. It is now possible to purchase this vaccine. Because of the size and structure of virosomes, it is possible to link many immunogenic proteins covalently to create multivalent vaccines [8]. In addition to interacting with a phospholipid bilayer and being dependent on influenza haemagglutinin, virosomes also inhibit liposome fusion. One of the most significant influenza antigens, haemagglutinin, is found in the two polypeptide subtypes, HA1 and HA2,

and it is complex in both membrane fusion and binding [9]. Figure 2.2.1 showed Virosomes medication delivery mechanism.

HA1 – Antigen-introducing cells [APCs] such as lymphocytes and macrophages have a strong propensity for sialic corrosive, which HA1 is ahead of in terms of its understanding of receptor sites.

HA2 – Without even a microsecond's delay, HA2 polypeptide intervenes to break the HA2/virosome endosomal layer bond [10].

Protein and peptide are delivered via virosomes e.g. The antibacterial, antimalarial, and antifungal properties of gelonin subunit A have been demonstrated in both in vitro and in vivo settings. Virosomes are employed in the realm of oncology as well [11].



Fig: 2.2.1 Virosomes medication delivery mechanism

2.3 Emulsion distribution infrastructure

Clinical usage of emulsion adjuvant has a long history. An emulsion’s a biphasic system, meaning that one phase loves water and the other phase hates it. There are several kinds of adjuvants in that, such as MF59 and AF03, depending on the strategy, system of activity, and clinical experience [12]. The licensed vaccines that are contained in the emulsion adjuvant are summarized in the table below. Novartis vaccine and diagnostics produced MF59, an emulsion adjuvant [13]. The flu vaccine Fluad, Aflunov, Focetria, and Celtura were originally licensed by a squalene oil-based emulsion. Their particle size is around 160 nm, and their mode of action promotes the synthesis of cytokinin and chemokines as well as creates the immunocompetent milieu. Furthermore, several formulation types exist, such as AS03, AF03, GLA-SE, Montanides, AS02, etc [14]. Antigen-presenting cells [APCs] are more persuaded by an oil-in-water [o/w] emulsion, which provides a rich environment in chemokines and cytokines. For the purpose of immunizing humans and animals, aluminium salt and oil emulsion products such as MF59 [Novartis], AS03, and AS04 [Glaxo Smith Kline] are now accessible [15]. Figure 2.3.1 showed system of emulsion.



Fig: 2.3.1 System of Emulsion

2.4 Delivery method for polymeric nanoparticles

Because of their cellular toxicity and autoimmunity, the nanomaterials suppress or destroy harmful cells. Delivery of polymeric nanoparticles has excellent biodegradability and very high biological safety. They prevent the antigen from deteriorating. Chitosan, polyglutamic acid [PGA], polylactic acid [PLA], poly[lactic-glycolic acid] [PLGA], and other polymers are found in polymer-based nanomaterials [16]. Table 2.4 shows Polymer and their application.

Table 2.4 Polymer and their application.

Polymer	**Application**
Chitosan	In relation to the medical bandage, genetic transmission.
Starch	Bone healing and drug delivery vehicles.
Alginate	Medical dressing and a patient.
Cellulose	Medicinal supplement.
Polyurethane	Applied to medicinal excipients and bandages.

A protective, invulnerable response is developed through the interchange of antigens to dendric cells. With the use of solvent antigen alone, dendritic cells are greatly increased. It is possible to obtain a 30-overlap development in take-up in some circumstances [17]. Figure 2.4 showed polymeric system.



Fig: 2.4 Polymeric system

2.5 Micellar administration technique

Self-assembling miracles in the micellar framework, which regulate the assembly's size and form in relation to the overall size of hydrophilic or hydrophobic squares, make it tremendously fascinating [18]. The two kinds of micellar nanocarriers are:

I. Amphiphilic copolymer block
II. Peptide amphiphiles are adjuvant micellar systems.

Micelles are core-shell nanoparticle self-assembly that generates a different hydrophilic or hydrophobic molecule. Invented by a Moyer describes the procedure and framework for creating a nontoxic and usable oral smallpox antibody for people utilizing the hereditarily damaged strain of vaccinia infection to chat resistance resulting oral conveyance of the immunization [13]. Figure 2.5.1 showed micellar delivery system.



Fig: 2.5.1 Micellar drug delivery system

2.6. Delivery mechanism based on dendrimers

An affinity ligand, radioligand, chemical species, targeting elements, imaging agents, therapeutic agents, radioligands, and dendrimers are a class of hyperbranched synthetic polymer systems that can be conjugated for various bioanalytical applications. Dendrimers feature thin sub-atomic weight transportation and a significant degree of atomic consistency [19]. They are taken up by the cell by endocytosis, which explains why the drug is attached to the cell's dendrimer [20]. Dendrimers make medication delivery, diagnosis, and treatment relatively simple. Furthermore, there is scientific proof supporting the efficacious dendrimer product, and it is simple to transfer its applications from the lab to the clinical setting. Treatment, diagnostics, and drug delivery are all made comparatively easy by dendrimers. Furthermore, the effective dendrimer product is supported by scientific evidence, and transferring its uses from the laboratory to the clinical setting is a straightforward process. Figure 2.6.1 showed rheumatoid arthritis

The following areas are the focus of future development:

I. Decrease the cost of dendrimer synthesis so that we can use it widely in the membrane.
II. Utilizing the dendric polymer's novel applicability in other membrane sectors.
III. The usage of hyperbranched polymers in the environment and resource fields is growing [21].



Fig: 2.6.1 Rheumatoid arthritis

In addition to its physicochemical characteristics, such as ionic strength, polarity and solvent PH, the dendrimer's attributes include monodispersity, polyvalency, and nanoscale size and form. Dendrimers are employed in many different syntheses, such as a multifunctional nano system that combines radiotherapeutics and other pharmaceuticals in a synergistic way or

uses convenient radicals and a variety of probes. The dendrimer facilitates the functional group's ideal fit. An additional physical signal is the primary application of electroactive organic radiation in molecular switches. The electron-accumulative molecule is subjected to a radical dendrimer [22].

2.7 Iscoms-Complex Immunostimulatory

When used in an antibody that is initially separated from the film protein of a parainfluenza-3 measles and rabies infection, the acronym ISCOMs is derived from the limit of the submicron molecule, which is an activity as immunostimulant complex in creatures [23].The particle known as the immunostimulant complex [ISCOMS] has additional antigen duplicates combined with an adjuvant. It gives the immune system an antigen presentation that is physically ideal [24]. Income Matrix, or Iscom, is a type of particle that does not include antigen. Saponins, also known as triterpenoids, are a special kind of compound found in income matrices. A distinct affinity for cholesterol is shown by Quillaia saponaria, which helps to maintain the consistency of the complex. As an adjuvant, ISCOMATRIXTM is a compound that lacks antigen but contains phospholipid, cholesterol, and saponin. Structure-wise, it is comparable to ISCOMs [25]. The majority of studies have demonstrated that ISCOMs and ISCOMMATRIXTM antibodies can stimulate strong humoral or cell responses to a broad range of antigens in various animal models [26]. Figure 2.7.1 showed complex of immunostimulatory agents.



Fig 2.7.1 Complex of immunostimulatory agents

2.8 Edible vaccine

Transgenic plants, animals, and/or those with operators that generate a creature resistant reaction are referred to as the edible antibody. The plants deliver the edible antibodies. A veterinary antibody is the principal plant-inferred immunization used in commerce [27]. The route is cleared by a prodi Gene Inc. emerged solely due to the fact that the plant's oral antibody could guarantee tamed animals near hazardous tasks. According to Dow AgroSciences, chicken vaccination is the first product to hit the market [28]. The initial

pathogen's DNA fragment is contained by edible antibodies, which are then used by the pathogen as its surface protein. The body's immunological reaction is caused by this. Regarding transgenic tomatoes to prevent diarrhea and edible vaccine transgenic potatoes to prevent diarrhea [29]. In order for edible vaccines to be developed in the future, genetically modified plants must be accepted by society and culture, genetically reformed types must be stable, transgenic plants must be appropriately segregated, and any potential allergy side effects must be anticipated. As an improved immunization method over the standard vaccine, the edible vaccine is both safer and more effective. Delivery and distribution are uneasy following mass production. As a result, expanding a delivery that is safe, effective, and economical is imperative [30]**.**Table 2.8 shows applications of edible vaccines and figure 2.8 showed edible circulate system.

Table 2.8 Applications of edible vaccines

Plants	**Application**
Wheat, rice	Cancer treatment
N.Tabacum	Tooth decay
Soyabean	Herpes
T.Benthamiana	Colon cancer
Hepatitis virus	Hepatitis



Fig: 2.8 Edible circulate System

2.9 Vaccination via mucosal delivery:

Although a designed beginning of a mucosal immunization has been created, there are different polymers from the characteristic in the mucosal conveyance of antibodies. The most important consideration when choosing a polymer for the mucosal delivery of an antibody is its toxicity, irritation, mucoadhesive ability, allergenicity, and biodegradability [31]. Mucosal resistant enrolment is a type of one-shot association between an antigen and a safe framework cell that ultimately triggers the acceptance of an immune response that is impervious [32]. Once breathing or digesting has taken place, the greatest eco-friendly pathogen passes the human body with the help of mucosa-related lymphoid tissue [MALT], which is then taken

up separately by gut-associated lymphoid tissue [GALT], nasal related lymphoid tissue [NALT], or bronchus-related lymphoid tissue [BALT] [33]. In veterinary medicine, mucosal immunization is of great assistance. For instance, drinking water and splash antibodies are frequently used for mass inoculation in poultry farming. An additional uniform mucosal delivery is advised by the present advancement of a palatable gel-dab based vaccination framework [34]. Figure 2.9.1 showed mucosal vaccination via the Respiratory Tract.



Fig: 2.9.1 Mucosal Vaccination via the Respiratory Tract

2.10 Needle-free delivery:

In the 1940s and 1950s, the first air-powered needle-free injection method was created to administer the vaccination to American soldiers in large quantities. To deliver millilitres of liquid onto the skin and muscle, the first injector uses compressed gas [35].An innovative approach to vaccine delivery, sans needle infusion uses an intriguing profile as the primary infusion stimulus to deliver the antibody to the appropriate tissue profundity [2]. This technique reduces needle stick injuries while being very less unpleasant and well accepted [36]. Figure 2.10.1 showed Needle-free System to Be Used in Australian Clinical COVID-19 Trial.



Fig: 2.10.1 Needle-free System to Be Used in Australian Clinical COVID-19 Trial

2.11 Jet Injection:

To administer medicine without needles into the desired tissue, a jet injection uses a squirt liquid under high density. France was the first to patent this technique in 1936, having devised it in the 1860s [37]. An oscillating 0.12 mm diameter orifice at the distal end of the jet injector oscillates between 0.05 and 0.36 mm to transmit into the patient by centering the current stream. The dosing chamber of the injector is strong enough to hold the liquid at that point, pressurizing a stirring piston at the proximal end to squeeze out liquids [38]. For many years, a jet injector was used to quickly immunize a large number of societies that were in need of vaccinations. However, in the event that issues arise, the new technology—a traditional syringe needle approach—must be used [39]. Some issues arise during infusion, such as injector stoppage, splatter, and sprinkle. A more recent method is the non-needle medicate delivery strategy [NFII], which involves a rapid flow of liquid that affects the skin to deliver sedatives that do not contain antibodies and are purposefully flooded treatments, such as insulin. The corticosteroid-containing liquid also contains bleomycin, 5-aminolevulinic corrosive [ALA], botulinum toxin A [BoNT-ONA], and other sedatives [40]. Figure 2.11.1 showed jet injection.



Fig: 2.11.1. Jet Injection

2.11.a. There are two kinds of needleless injectors

I. Spring-loaded jet injector
II. Gasoline-powered jet injector

A spring system powers a variety of jet injector spring-stacked instruments. When the spring is activated by pulling a trigger, the drug's fly stream is prompted to age, allowing for a medication swap. The gas fuelled device is an air cartridge that is located close to the weapon and has a tubing framework closed around it that transmits control to the cylinder and then generates activation [41].

2.12 Microneedles:

A fixed framework is used in conjunction with a microneedle and a standard infusion framework. To distribute the medicine through holes, a microneedle is poked into the stratum corneum and then the skin. There are four different types of microneedles: hollow, coated, dissolving, and solid [42]. The material that makes up quadrangular pyramids or shafts that are tens or hundreds of micrometres long is called a microneedle. The microneedle's primary benefit is that it works well with immunization routes [43]. The significant amount of research on microfabrication and vaccine administration methods that is now accessible in this field clearly indicates the promise of dissolving microneedles [44]. Reporting regulatory issues and providing feature control tests to support the development of microarray technology are the goals of the PATH center of excellence [45]. The hollow microneedle offers a pre-planned route for injecting vaccines into tissue or skin. Currently, single microneedles and mini-needles are hollow microneedles. It is possible to immunize human subjects against influenza or polio, protect mice from the plague, and administer polio vaccine to rats using hollow microneedles [19]. Figure 2.12.1 showed Microneedles for Transdermal Drug Delivery.



Fig: 2.12.1 Microneedles for Transdermal Drug Delivery

3. Future prospective:

Lessening the require for different measurements of an immunization by boosting the body's safe reaction. Making strides fabricating forms to convey antibody dosages more rapidly [46]. Making transportation and capacity of immunizations simpler to decrease wastage and progress get to for difficult to reach communities and changes may incorporate the expansion of novel injectable adjuvants or the utilize of novel courses of conveyance, counting mucosal immunization. Mucosal conveyance may be required to supply assurance against pathogens that contaminate at mucosal destinations, counting sexually transmitted illnesses [20].

4. Challenges

A significant great issue is the development of thermostable vaccination lozenge forms that can be individually packaged, stored, and sent via a valuable cold chain, such as to isolated regions in developing nations. Most vaccines are made in the form of liquid tablets that should be kept refrigerated [47]. For example, Spikevax will remain stable at 20°C for more than 6 months whereas Comirnaty needs to be stored at 70°C due to the necessity of technical freezers and transport conditions [48]. Solid tablets forms are frequently manufactured using drying processes like snap drying or spray drying, and addition of cryo- or cytoprotectants, e.g., trehalose, sucrose and mannitol, is demanded to stabilize vaccines during drying and in the solid state and save vaccine stability and energy. In order to ensure that the long term safety of immunisations at encompassing temperatures is maintained, it is almost necessary to provide basic information about how to stabilize complex antibodies in a strong state [49]. Inevitably, the problem of designing a vaccine to teach susceptible systems how to beat and destroy cancer cells is still far from solved [50]. Remedial cancer vaccines should induce cytotoxic CD8 T cells capable of killing cancer cells, but more knowledge is needed on the selection of excrescence associated antigens, adjuvants, and how to overcome the immunosuppressive medium of excrescence [51]. In particular, it seems that the mRNA vaccine platform will have a major impact on cancer therapy. The substantiated use of cancer vaccines against neoantigens, which are unique to each case, is an interesting approach. Remaining challenges, among others, also include how to design

I. single- cure vaccines that are largely efficient in one cure and induces robust and lifelong impunity, and
II. needle-free vaccine delivery technologies with bettered access and compliance [52].

5. Strategies

The innate immune system is fundamentally implicated in mechanisms of immune activation [and possibly also adjuvant efficacy] through the recognition of pathogen associated microbial patterns by receptors on innate immune cells [pathogen recognition receptors] such as Toll-like receptors, mannose receptors or complement receptors [53]. Without a doubt, compared to the use of whole-cell or live vaccines, the creation of component vaccines has

occasionally resulted in a lower rate of adverse responses. This is exemplified in the widespread use today of the acellular pertussis vaccine [54]. The potential and difficulties that currently exist in the development and delivery of vaccines are helping to facilitate a highly fluid, diversified and interesting period for vaccination research. The diversity of vaccine delivery systems that are being developed for an increasingly diverse range of medicinal and prophylactic uses is demonstrated by the articles which have been presented in this Special Issue of Journal of Drug Targeting, with a focus on strategies to deliver vaccines [55].

6. Conclusion:

Due to the focal points, they give, antibody pharmaceutical conveyance frameworks are getting to be increasingly common nowadays. As they don't require booster measurements and offer a long-term treatment in minor dosages, antibody sedate conveyance frameworks are presently appearing to be quiet charming. The selection of needle-free innovation to manage them encourage advances their utilize. On the other hand, eatable antibodies offer an appealing strategy for the verbal organization of immunizations.

Conflict Of Interest:

The authors have no conflict of interest to declare.

Ethical Approval:

This article does not contain any studies with human participants or animals performed by any of the authors.

Funding:

There is no involvement of any organization in funding on this review.

References:

[1] Apostolopoulos V. Vaccine Delivery Methods into the Future. Vaccines 2016;4:9. https://doi.org/10.3390/vaccines4020009.

[2] Arora A, Hakim I, Baxter J, Rathnasingham R, Srinivasan R, Fletcher DA, et al. Needle-free delivery of macromolecules across the skin by nanoliter-volume pulsed microjets. Proc Natl Acad Sci 2007;104:4255–60. https://doi.org/10.1073/pnas.0700182104.

[3] Daemen T, de Mare A, Bungener L, de Jonge J, Huckriede A, Wilschut J. Virosomes for antigen and DNA delivery. Adv Drug Deliv Rev 2005;57:451–63. https://doi.org/10.1016/j.addr.2004.09.005.

[4] Han J, Zhao D, Li D, Wang X, Jin Z, Zhao K. Polymer-based nanomaterials and applications for vaccines and drugs. Polymers 2018;10:31.

[5] Mondal S, Hazra A, Ghosh K, Dey I, Bhowmick P, Bhowmick M. Intergraded multi omics analysis identifies antiviral host factor and pathway controlling HIV infection. World J Biol Pharm Health Sci 2025;22:608–23. https://doi.org/10.30574/wjbphs.2025.22.1.0437.

[6] Saroja CH, Lakshmi PK, Bhaskaran S. Recent trends in vaccine delivery systems: a review. Int J Pharm Investig 2011;1:64.

[7] Prajapati SK, Maurya SD, Das MK, Tilak VK, Verma KK, Dhakar RC. DENDRIMERS IN DRUG DELIVERY, DIAGNOSIS AND THERAPY: BASICS AND POTENTIAL APPLICATIONS. J Drug Deliv Ther 2016;6:67–92. https://doi.org/10.22270/jddt.v6i1.1190.

[8] Thompson KM, Orenstein WA, Hinman AR. An opportunity to incentivize innovation to increase vaccine safety in the United States by improving vaccine delivery using vaccine patches. Vaccine 2020;38:4060–5. https://doi.org/10.1016/j.vaccine.2020.04.044.

[9] Desai SN, Kamat D. Closing the Global Immunization Gap: Delivery of Lifesaving Vaccines Through Innovation and Technology. Pediatr Rev 2014;35:e32–40. https://doi.org/10.1542/pir.35-7-e32.

[10] Trovato M, Berardinis PD. Novel antigen delivery systems. World J Virol 2015;4:156–68. https://doi.org/10.5501/wjv.v4.i3.156.

[11] Huang J, Yuen D, Mintern JD, Johnston APR. Opportunities for innovation: Building on the success of lipid nanoparticle vaccines. Curr Opin Colloid Interface Sci 2021;55:101468. https://doi.org/10.1016/j.cocis.2021.101468.

[12] Desai DN, Mahal A, Varshney R, Obaidullah AJ, Gupta B, Mohanty P, et al. Nanoadjuvants: Promising Bioinspired and Biomimetic Approaches in Vaccine Innovation. ACS Omega 2023;8:27953–68. https://doi.org/10.1021/acsomega.3c02030.

[13] Kasturi SP, Skountzou I, Albrecht RA, Koutsonanos D, Hua T, Nakaya HI, et al. Programming the magnitude and persistence of antibody responses with innate immunity. Nature 2011;470:543–7.

[14] Vaccine delivery: where polymer chemistry meets immunology | Therapeutic Delivery n.d. https://www.future-science.com/doi/full/10.4155/tde-2016-0008 (accessed February 26, 2024).

[15] Kumru OS, Joshi SB, Smith DE, Middaugh CR, Prusik T, Volkin DB. Vaccine instability in the cold chain: Mechanisms, analysis and formulation strategies. Biologicals 2014;42:237–59. https://doi.org/10.1016/j.biologicals.2014.05.007.

[16] Kumari A, Yadav SK, Yadav SC. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B Biointerfaces 2010;75:1–18. https://doi.org/10.1016/j.colsurfb.2009.09.001.

[17] Hickey JW, Santos JL, Williford J-M, Mao H-Q. Control of polymeric nanoparticle size to improve therapeutic delivery. J Controlled Release 2015;219:536–47. https://doi.org/10.1016/j.jconrel.2015.10.006.

[18] Matsumura Y. Polymeric Micellar Delivery Systems in Oncology. Jpn J Clin Oncol 2008;38:793–802. https://doi.org/10.1093/jjco/hyn116.

[19] Kendall M. Engineering of needle-free physical methods to target epidermal cells for DNA vaccination. Vaccine 2006;24:4651–6. https://doi.org/10.1016/j.vaccine.2005.08.066.
[20] Kling HM, Nau GJ, Ross TM, Evans TG, Chakraborty K, Empey KM, et al. Challenges and Future in Vaccines, Drug Development, and Immunomodulatory Therapy. Ann Am Thorac Soc 2014;11:S201–10. https://doi.org/10.1513/AnnalsATS.201401-036PL.
[21] France R, Rumpe B. Model-driven Development of Complex Software: A Research Roadmap. Future Softw. Eng. FOSE 07, 2007, p. 37–54. https://doi.org/10.1109/FOSE.2007.14.
[22] Shahidi F, Wanasundara UN. Omega-3 fatty acid concentrates: nutritional aspects and production technologies. Trends Food Sci Technol 1998;9:230–40. https://doi.org/10.1016/S0924-2244(98)00044-2.
[23] Ardichvili A, Cardozo R, Ray S. A theory of entrepreneurial opportunity identification and development. J Bus Ventur 2003;18:105–23. https://doi.org/10.1016/S0883-9026(01)00068-4.
[24] Lewis MW, Smith WK. Paradox as a Metatheoretical Perspective: Sharpening the Focus and Widening the Scope. J Appl Behav Sci 2014;50:127–49. https://doi.org/10.1177/0021886314522322.
[25] Rezania S, Oryani B, Park J, Hashemi B, Yadav KK, Kwon EE, et al. Review on transesterification of non-edible sources for biodiesel production with a focus on economic aspects, fuel properties and by-product applications. Energy Convers Manag 2019;201:112155. https://doi.org/10.1016/j.enconman.2019.112155.
[26] Hu K-F, Lövgren-Bengtsson K, Morein B. Immunostimulating complexes (ISCOMs) for nasal vaccination. Adv Drug Deliv Rev 2001;51:149–59. https://doi.org/10.1016/S0169-409X(01)00165-X.
[27] Lal P, Ramachandran V, Goyal R, Sharma R. EDIBLE VACCINES: CURRENT STATUS AND FUTURE. Indian J Med Microbiol 2007;25:93–102. https://doi.org/10.1016/S0255-0857(21)02165-4.
[28] Sohrab SS. An edible vaccine development for coronavirus disease 2019: the concept. Clin Exp Vaccine Res 2020;9:164–8. https://doi.org/10.7774/cevr.2020.9.2.164.
[29] Aryamvally A, Gunasekaran V, Narenthiran KR, Pasupathi R. New Strategies Toward Edible Vaccines: An Overview. J Diet Suppl 2017;14:101–16. https://doi.org/10.3109/19390211.2016.1168904.
[30] Liang J, Zhao X. Nanomaterial-based delivery vehicles for therapeutic cancer vaccine development. Cancer Biol Med 2021;18:352–71. https://doi.org/10.20892/j.issn.2095-3941.2021.0004.
[31] De Magistris MT. Mucosal delivery of vaccine antigens and its advantages in pediatrics. Adv Drug Deliv Rev 2006;58:52–67. https://doi.org/10.1016/j.addr.2006.01.002.
[32] Woodrow KA, Bennett KM, Lo DD. Mucosal Vaccine Design and Delivery. Annu Rev Biomed Eng 2012;14:17–46. https://doi.org/10.1146/annurev-bioeng-071811-150054.

[33] Rhee JH. Chapter 19 - Current and New Approaches for Mucosal Vaccine Delivery. In: Kiyono H, Pascual DW, editors. Mucosal Vaccines Second Ed., Academic Press; 2020, p. 325–56. https://doi.org/10.1016/B978-0-12-811924-2.00019-5.

[34] Dewangan HK. Rational application of nanoadjuvant for mucosal vaccine delivery system. J Immunol Methods 2020;481–482:112791. https://doi.org/10.1016/j.jim.2020.112791.

[35] Giudice EL, Campbell JD. Needle-free vaccine delivery. Adv Drug Deliv Rev 2006;58:68–89. https://doi.org/10.1016/j.addr.2005.12.003.

[36] Kale TR, Momin M. Needle free injection technology - An overview. Innov Pharm 2014;5. https://doi.org/10.24926/iip.v5i1.330.

[37] Chen X, Fernando GJP, Crichton ML, Flaim C, Yukiko SR, Fairmaid EJ, et al. Improving the reach of vaccines to low-resource regions, with a needle-free vaccine delivery device and long-term thermostabilization. J Controlled Release 2011;152:349–55. https://doi.org/10.1016/j.jconrel.2011.02.026.

[38] Shah UU, Roberts M, Orlu Gul M, Tuleu C, Beresford MW. Needle-free and microneedle drug delivery in children: A case for disease-modifying antirheumatic drugs (DMARDs). Int J Pharm 2011;416:1–11. https://doi.org/10.1016/j.ijpharm.2011.07.002.

[39] Elsabahy M, Foldvari M. Needle-free Gene Delivery Through the Skin: An Overview of Recent Strategies. Curr Pharm Des 2013;19:7301–15.

[40] Patni P, Varghese D, Balekar N, Jain D. Needle-free insulin drug delivery. Indian J Pharm Sci 2006;68.

[41] Chase CCL. Needle-free injection technology in swine: Progress toward vaccine efficacy and pork quality. J Swine Health Prod 2008;16:254–61.

[42] Michinaka Y, Mitragotri S. Delivery of polymeric particles into skin using needle-free liquid jet injectors. J Controlled Release 2011;153:249–54. https://doi.org/10.1016/j.jconrel.2011.03.024.

[43] Mangla B, Javed S, Sultan MH, Ahsan W, Aggarwal G, Kohli K. Nanocarriers-Assisted Needle-Free Vaccine Delivery Through Oral and Intranasal Transmucosal Routes: A Novel Therapeutic Conduit. Front Pharmacol 2022;12.

[44] Rohilla P, Lawal I, Le Blanc A, O'Brien V, Weeks C, Tran W, et al. Loading effects on the performance of needle-free jet injections in different skin models. J Drug Deliv Sci Technol 2020;60:102043. https://doi.org/10.1016/j.jddst.2020.102043.

[45] Ruddy BP, Bullen C, Chu JTW, Jeong SH, Madadkhahsalmassi B, McKeage JW, et al. Subcutaneous nicotine delivery via needle-free jet injection: A porcine model. J Controlled Release 2019;306:83–8. https://doi.org/10.1016/j.jconrel.2019.05.040.

[46] van Drunen Littel-van den Hurk S, Loehr BI, Babiuk LA. Immunization of livestock with DNA vaccines: current studies and future prospects. Vaccine 2001;19:2474–9. https://doi.org/10.1016/S0264-410X(00)00476-X.

[47] Keith JA, Agostini Bigger L, Arthur PA, Maes E, Daems R. Delivering the promise of the Decade of Vaccines: Opportunities and challenges in the

development of high quality new vaccines. Vaccine 2013;31:B184–93. https://doi.org/10.1016/j.vaccine.2012.12.032.

[48] Guignard A, Praet N, Jusot V, Bakker M, Baril L. Introducing new vaccines in low- and middle-income countries: challenges and approaches. Expert Rev Vaccines 2019;18:119–31. https://doi.org/10.1080/14760584.2019.1574224.

[49] Excler J-L, Privor-Dumm L, Kim JH. Supply and delivery of vaccines for global health. Curr Opin Immunol 2021;71:13–20. https://doi.org/10.1016/j.coi.2021.03.009.

[50] Ford AQ, Touchette N, Hall BF, Hwang A, Hombach J. Global Vaccine and Immunization Research Forum: Opportunities and challenges in vaccine discovery, development, and delivery. Vaccine 2016;34:1489–95. https://doi.org/10.1016/j.vaccine.2015.11.038.

[51] Han L, Peng K, Qiu L-Y, Li M, Ruan J-H, He L-L, et al. Hitchhiking on Controlled-Release Drug Delivery Systems: Opportunities and Challenges for Cancer Vaccines. Front Pharmacol 2021;12.

[52] Tan LJ, Barnett MA, Eisenberg A, Fox Fields H, Hackell JM, Léger MM, et al. From refrigerator to arm: Issues in vaccination delivery. Vaccine 2014;32:2389–93. https://doi.org/10.1016/j.vaccine.2014.02.045.

[53] Ilin I, Levina A, Frolov K. Innovative Ecosystem Model of Vaccine Lifecycle Management. J Open Innov Technol Mark Complex 2022;8:5. https://doi.org/10.3390/joitmc8010005.

[54] Mao W, Zimmerman A, Hodges EU, Ortiz E, Dods G, Taylor A, et al. Comparing research and development, launch, and scale up timelines of 18 vaccines: lessons learnt from COVID-19 and implications for other infectious diseases. BMJ Glob Health 2023;8:e012855. https://doi.org/10.1136/bmjgh-2023-012855.

[55] Hanly M, Churches T, Fitzgerald O, Caterson I, MacIntyre CR, Jorm L. Modelling vaccination capacity at mass vaccination hubs and general practice clinics 2021:2021.04.07.21255067. https://doi.org/10.1101/2021.04.07.21255067.